Ivor

Bemiparin Sodium, the active ingredient in Ivor, is a low molecular weight heparin presented as a subcutaneous injection for subcutaneous use. It is employed to prevent venous thromboembolism, treat deep vein thrombosis, and reduce thromboembolic complications in patients undergoing surgery. The drug activates antithrombin III, leading to inhibition of factor Xa and, to a lesser extent, factor IIa. Its predictable pharmacokinetic profile allows once‑daily administration in most clinical settings.

GNH USA supplies Ivor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bemiparin Sodium is indicated for anticoagulation in several clinical scenarios related to venous clot formation.

Prevention of venous thromboembolism: reduces incidence of deep vein thrombosis and pulmonary embolism in at‑risk patients. Treatment of deep vein thrombosis: facilitates clot resolution and prevents propagation of existing thrombi. Surgical prophylaxis of thromboembolic complications: lowers risk of postoperative clot formation in patients undergoing major surgery.

Bemiparin Sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema - Bruising or hematoma at the injection site - Mild bleeding (e.g., epistaxis, gum bleeding) - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal) - Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT) - Severe allergic reactions (anaphylaxis, urticaria) - Spinal or epidural hematoma following neuraxial procedures - Skin necrosis at the injection site - Pulmonary embolism despite therapy

When prescribing Bemiparin Sodium, clinicians should consider several safety aspects.

Renal impairment: assess renal function and monitor anti‑Xa levels if needed. History of bleeding disorders: evaluate risk before initiating therapy. Concurrent use of other anticoagulants or antiplatelet agents: avoid unless medically justified. Pregnancy and lactation: use only if potential benefit outweighs risk. Surgical procedures: discontinue prior to major surgery according to clinical guidelines. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Bemiparin Sodium can interact with other medicines that affect hemostasis.

Major Interactions (Avoid): - Warfarin: additive anticoagulant effect increasing bleeding risk. - Direct oral anticoagulants (e.g., apixaban, rivaroxaban): combined therapy may cause severe hemorrhage. - Thrombolytic agents (e.g., alteplase): heightened risk of major bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Antiplatelet drugs (e.g., clopidogrel, aspirin): additive effect on platelet inhibition. - Selective serotonin reuptake inhibitors (SSRIs): potential for impaired platelet aggregation.